Michael Lewitt, MD, discusses personalized management strategiesfor plaque psoriasis (PsO) through comprehensive case studies, highlighting treatment approaches for diverse patients, including a new mother seeking needle-free options, a 55-year-old man with psoriatic arthritis (PsA) and PsO, and a 7-year-old child with a recent PsO diagnosis, emphasizing the importance of tailored therapies based on each patient’s lifestyle, age, and specific needs.
EP. 1: Case 1: A new Mom Looking for a PsO Treatment That Fits Into Her Lifestyle
November 12th 2024Michael Lewitt, MD, provides an overview of Case-Based Roundtable and introduces a case involving a patient with a 10-year history of plaque psoriasis (PsO) in sensitive areas, discussing the significant impact on quality of life, the patient’s aversion to needles as a new mom, and the exploration of biologic therapies as a treatment option.
EP. 2: Case 2: A 55-Year-Old Man With PsO and PsA
November 12th 2024Michael Lewitt, MD, discusses a case involving a 55-year-old man with psoriasis (PsO) and psoriatic arthritis (PsA), highlighting challenges such as treatment for sensitive areas like the palms, soles, and scalp, mild morning stiffness, and the patient’s dissatisfaction with prior topical treatments; the discussion includes systemic and topical steroid use, concerns about TNF inhibitors, the effectiveness of phototherapy on limited areas, and the potential adverse events associated with the apremilast standard dose regimen, with phototherapy considered as a rescue option for flares.
EP. 3: A 7-Year-Old Girl With a Recent PsO Diagnosis
November 12th 2024Michael Lewitt, MD, discusses a case involving a 7-year-old girl with plaque psoriasis (PsO) affecting body surface area (BSA) and the face, emphasizing the limited pediatric treatment options and the psychological and social impact on the child; the family initially opted for topical treatments like roflumilast, but preferred a more proactive approach, transitioning to apremilast while addressing concerns about gastrointestinal adverse events and the patient’s aversion to needles.